Johnson & Johnson annual gross margin
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson Gross Margin Growth & History (JNJ)
Johnson & Johnson's gross margin was 67.88% for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-28 | 67.88% | −1.19 pp |
| 2024 | 2024-12-29 | 69.07% | +0.25 pp |
| 2023 | 2023-12-31 | 68.82% | −0.43 pp |
| 2022 | 2023-01-01 | 69.25% | −1.03 pp |
| 2021 | 2022-01-02 | 70.28% | +4.70 pp |
| 2020 | 2021-01-04 | 65.58% | −0.84 pp |
| 2019 | 2019-12-29 | 66.42% | −0.37 pp |
| 2018 | 2018-12-30 | 66.79% | +0.07 pp |
| 2017 | 2017-12-31 | 66.72% | −2.97 pp |
| 2016 | 2017-01-01 | 69.69% | +0.42 pp |
| 2015 | 2016-01-03 | 69.27% | −0.13 pp |
| 2014 | 2014-12-28 | 69.40% | +0.73 pp |
| 2013 | 2013-12-29 | 68.67% | +0.89 pp |
| 2012 | 2012-12-30 | 67.78% | −0.91 pp |
| 2011 | 2012-01-01 | 68.69% | −0.80 pp |
| 2010 | 2011-01-02 | 69.49% | −0.71 pp |
| 2009 | 2010-01-03 | 70.20% | −0.76 pp |
| 2008 | 2008-12-28 | 70.96% | +0.02 pp |
| 2007 | 2007-12-30 | 70.95% | — |
Johnson & Johnson quarterly gross margin
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-28 | 68.19% | +0.32 pp |
| Q1 2026 | 2026-03-29 | 66.31% | −0.08 pp |
| Q4 2025 | 2025-12-28 | 67.56% | −0.79 pp |
| Q3 2025 | 2025-09-28 | 69.56% | +0.55 pp |
| Q2 2025 | 2025-06-29 | 67.87% | −1.53 pp |
| Q1 2025 | 2025-03-30 | 66.40% | −3.15 pp |
| Q4 2024 | 2024-12-29 | 68.35% | +0.12 pp |
| Q3 2024 | 2024-09-29 | 69.01% | −0.05 pp |
| Q2 2024 | 2024-06-30 | 69.40% | −0.57 pp |
| Q1 2024 | 2024-03-31 | 69.55% | +1.55 pp |
| Q4 2023 | 2023-12-31 | 68.23% | −1.26 pp |
| Q3 2023 | 2023-10-01 | 69.06% | −0.07 pp |
| Q2 2023 | 2023-07-02 | 69.97% | +1.24 pp |
| Q1 2023 | 2023-04-02 | 68.00% | −1.67 pp |
| Q4 2022 | 2023-01-01 | 69.49% | −15.14 pp |
| Q3 2022 | 2022-10-02 | 69.13% | +0.20 pp |
| Q2 2022 | 2022-07-03 | 68.73% | +1.27 pp |
| Q1 2022 | 2022-04-03 | 69.67% | +1.31 pp |
| Q4 2021 | 2022-01-02 | 84.62% | +19.39 pp |
| Q3 2021 | 2021-10-03 | 68.93% | +2.01 pp |
| Q2 2021 | 2021-07-04 | 67.45% | +3.33 pp |
| Q1 2021 | 2021-04-04 | 68.36% | +2.49 pp |
| Q4 2020 | 2021-01-04 | 65.23% | −0.38 pp |
| Q3 2020 | 2020-09-27 | 66.93% | +0.06 pp |
| Q2 2020 | 2020-06-28 | 64.12% | −2.13 pp |
| Q1 2020 | 2020-03-29 | 65.87% | −1.09 pp |
| Q4 2019 | 2019-12-29 | 65.61% | −0.25 pp |
| Q3 2019 | 2019-09-29 | 66.87% | −0.75 pp |
| Q2 2019 | 2019-06-30 | 66.25% | −0.50 pp |
| Q1 2019 | 2019-03-31 | 66.96% | +0.01 pp |
| Q4 2018 | 2018-12-30 | 65.87% | +1.81 pp |
| Q3 2018 | 2018-09-30 | 67.62% | +2.86 pp |
| Q2 2018 | 2018-07-01 | 66.75% | −2.22 pp |
| Q1 2018 | 2018-04-01 | 66.94% | −2.61 pp |
| Q4 2017 | 2017-12-31 | 64.06% | −5.38 pp |
| Q3 2017 | 2017-10-01 | 64.76% | −4.46 pp |
| Q2 2017 | 2017-07-02 | 68.97% | −2.16 pp |
| Q1 2017 | 2017-04-02 | 69.55% | +0.04 pp |
| Q4 2016 | 2017-01-01 | 69.44% | +1.29 pp |
| Q3 2016 | 2016-10-02 | 69.21% | −0.24 pp |
| Q2 2016 | 2016-07-03 | 71.13% | +1.25 pp |
| Q1 2016 | 2016-04-03 | 69.52% | −0.08 pp |
| Q4 2015 | 2016-01-03 | 68.15% | +0.21 pp |
| Q3 2015 | 2015-09-27 | 69.45% | −1.31 pp |
| Q2 2015 | 2015-06-28 | 69.88% | +0.86 pp |
| Q1 2015 | 2015-03-29 | 69.60% | −0.29 pp |
| Q4 2014 | 2014-12-28 | 67.94% | +0.38 pp |
| Q3 2014 | 2014-09-28 | 70.76% | +1.17 pp |
| Q2 2014 | 2014-06-29 | 69.02% | −0.27 pp |
| Q1 2014 | 2014-03-30 | 69.89% | +1.61 pp |
| Q4 2013 | 2013-12-29 | 67.56% | +1.75 pp |
| Q3 2013 | 2013-09-29 | 69.59% | +2.42 pp |
| Q2 2013 | 2013-06-30 | 69.30% | +0.51 pp |
| Q1 2013 | 2013-03-31 | 68.27% | −1.27 pp |
| Q4 2012 | 2012-12-30 | 65.81% | −1.35 pp |
| Q3 2012 | 2012-09-30 | 67.18% | −1.13 pp |
| Q2 2012 | 2012-07-01 | 68.78% | −0.05 pp |
| Q1 2012 | 2012-04-01 | 69.55% | −0.91 pp |
| Q4 2011 | 2012-01-01 | 67.16% | −0.62 pp |
| Q3 2011 | 2011-10-02 | 68.31% | −1.03 pp |
| Q2 2011 | 2011-07-03 | 68.84% | −0.96 pp |
| Q1 2011 | 2011-04-03 | 70.46% | −0.57 pp |
| Q4 2010 | 2011-01-02 | 67.78% | −0.12 pp |
| Q3 2010 | 2010-10-03 | 69.34% | −1.26 pp |
| Q2 2010 | 2010-07-04 | 69.80% | −1.00 pp |
| Q1 2010 | 2010-04-04 | 71.03% | −0.68 pp |
| Q4 2009 | 2010-01-03 | 67.91% | — |
| Q3 2009 | 2009-09-27 | 70.60% | +0.58 pp |
| Q2 2009 | 2009-06-28 | 70.80% | −0.32 pp |
| Q1 2009 | 2009-03-29 | 71.71% | — |
| Q3 2008 | 2008-09-28 | 70.01% | — |
| Q2 2008 | 2008-06-29 | 71.12% | — |
Johnson & Johnson gross margin trends
Over the last five fiscal years, Johnson & Johnson's gross margin increased from 65.58% to 67.88%, a change of +2.30 percentage points. The latest reported quarter, Q2 2026, shows 68.19%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
